

Department of Health and Human Services

**OFFICE OF  
INSPECTOR GENERAL**

**MEDICARE PAYMENTS TO JURISDICTION  
14 PHYSICIANS FOR FULL VIALS OF  
HERCEPTIN WERE GENERALLY  
CORRECT**

*Inquiries about this report may be addressed to the Office of Public Affairs at  
[Public.Affairs@oig.hhs.gov](mailto:Public.Affairs@oig.hhs.gov).*



David Lamir  
Acting Regional Inspector  
General

June 2013  
A-01-12-00514

# *Office of Inspector General*

<https://oig.hhs.gov>

---

The mission of the Office of Inspector General (OIG), as mandated by Public Law 95-452, as amended, is to protect the integrity of the Department of Health and Human Services (HHS) programs, as well as the health and welfare of beneficiaries served by those programs. This statutory mission is carried out through a nationwide network of audits, investigations, and inspections conducted by the following operating components:

## *Office of Audit Services*

The Office of Audit Services (OAS) provides auditing services for HHS, either by conducting audits with its own audit resources or by overseeing audit work done by others. Audits examine the performance of HHS programs and/or its grantees and contractors in carrying out their respective responsibilities and are intended to provide independent assessments of HHS programs and operations. These assessments help reduce waste, abuse, and mismanagement and promote economy and efficiency throughout HHS.

## *Office of Evaluation and Inspections*

The Office of Evaluation and Inspections (OEI) conducts national evaluations to provide HHS, Congress, and the public with timely, useful, and reliable information on significant issues. These evaluations focus on preventing fraud, waste, or abuse and promoting economy, efficiency, and effectiveness of departmental programs. To promote impact, OEI reports also present practical recommendations for improving program operations.

## *Office of Investigations*

The Office of Investigations (OI) conducts criminal, civil, and administrative investigations of fraud and misconduct related to HHS programs, operations, and beneficiaries. With investigators working in all 50 States and the District of Columbia, OI utilizes its resources by actively coordinating with the Department of Justice and other Federal, State, and local law enforcement authorities. The investigative efforts of OI often lead to criminal convictions, administrative sanctions, and/or civil monetary penalties.

## *Office of Counsel to the Inspector General*

The Office of Counsel to the Inspector General (OCIG) provides general legal services to OIG, rendering advice and opinions on HHS programs and operations and providing all legal support for OIG's internal operations. OCIG represents OIG in all civil and administrative fraud and abuse cases involving HHS programs, including False Claims Act, program exclusion, and civil monetary penalty cases. In connection with these cases, OCIG also negotiates and monitors corporate integrity agreements. OCIG renders advisory opinions, issues compliance program guidance, publishes fraud alerts, and provides other guidance to the health care industry concerning the anti-kickback statute and other OIG enforcement authorities.

# *Notices*

---

## **THIS REPORT IS AVAILABLE TO THE PUBLIC**

at <https://oig.hhs.gov>

Section 8L of the Inspector General Act, 5 U.S.C. App., requires that OIG post its publicly available reports on the OIG Web site.

## **OFFICE OF AUDIT SERVICES FINDINGS AND OPINIONS**

The designation of financial or management practices as questionable, a recommendation for the disallowance of costs incurred or claimed, and any other conclusions and recommendations in this report represent the findings and opinions of OAS. Authorized officials of the HHS operating divisions will make final determination on these matters.

## INTRODUCTION

### WHY WE DID THIS REVIEW

When a physician administers a dose of a drug from a multiuse vial to a beneficiary, Medicare Part B will pay only for the amount of the drug actually administered, and any discarded amount is not reimbursable. A multiuse vial contains more than one dose of medication, as labeled by the manufacturer. Herceptin is packaged in multiuse vials of 440 milligrams and is a relatively expensive<sup>1</sup> drug used to treat breast cancer that has spread to other parts of the body. Based on prior audit work at outpatient providers,<sup>2</sup> we found that doses billed in multiples of the entire vial size (e.g., 440 milligrams, 880 milligrams, etc.) may include amounts of discarded drug billed in error. Medicare Part B and the beneficiaries are responsible only for the payment for the amount of the drug actually administered.

### OBJECTIVE

Our objective was to determine whether Medicare payments that NHIC, Corp. (NHIC), made to physicians in Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont for full vials of Herceptin furnished during CYs 2009 through 2011 were correct.

### BACKGROUND

#### The Medicare Program

The Medicare program provides health insurance for people aged 65 and over and those who are disabled or have permanent kidney disease. The Centers for Medicare & Medicaid Services (CMS) administers the program. CMS contracts with Medicare administrative contractors (MAC) to process and pay Medicare claims submitted for physician services. NHIC is the Medicare contractor for Jurisdiction 14, which includes Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont.

#### Claims for Drugs

Medicare guidance requires physicians to submit accurate claims for Part B services. Each submitted Medicare claim contains line items that detail each provided service. Physicians should use the appropriate Healthcare Common Procedure Coding Systems (HCPCS) code for the drug administered and report units of service in multiples of the units shown in the HCPCS narrative description. Multiuse vials are not subject to payment for discarded amounts of the

---

<sup>1</sup> Jurisdiction 14 physicians were paid a total of approximately \$8.2 million for Herceptin furnished during calendar years (CY) 2009 through 2011. During this period, physicians were paid approximately \$2,250 for a full vial (440 milligrams) of Herceptin.

<sup>2</sup> For example, see *Medicare Contractors' Payments in Jurisdiction 14 For Full Vials of Herceptin Were Often Incorrect* (A-01-11-00539), August 17, 2012. Available online at <https://oig.hhs.gov/oas/reports/region1/11100539.pdf>. Accessed March 8, 2013.

drug. Multiuse vials are typically used for more than one date of service and can be stored for up to 28 days. Therefore, a payment for an entire multiuse vial may include amounts of discarded drug billed in error.

## **Herceptin**

Herceptin is a monoclonal antibody, one of a group of drugs designed to attack specific cancer cells. The manufacturer supplies the drug in a carton containing a multiuse vial of 440 milligrams of Herceptin and one 20-milliliter vial of bacteriostatic water for injection (BWFI) containing a solution of 1.1 percent of benzyl alcohol as a preservative. A vial of Herceptin, when reconstituted with BWFI and stored properly, can be used for up to 28 days. When a patient is allergic to benzyl alcohol, sterile water without a preservative should be used and any unused portion of the mixture discarded. The HCPCS code for Herceptin is J9355, with a narrative description of “injection, trastuzumab 10mg.” An entire multiuse vial of 440 milligrams of reconstituted Herceptin when administered would be reported as 44 units for Medicare billing.

## **HOW WE CONDUCTED THIS REVIEW**

We used CMS’s National Claims History file to identify Part B line items which represented payments to physicians in Jurisdiction 14 for entire vials of Herceptin furnished during CYs 2009 through 2011. We found 113 line items with unit counts of 44, totaling approximately \$240,028, which NHIC paid to 22 physicians. We reviewed medical records to determine whether each line item was billed correctly.

We conducted this performance audit in accordance with generally accepted government auditing standards. Those standards require that we plan and perform the audit to obtain sufficient, appropriate evidence to provide a reasonable basis for our findings and conclusions based on our audit objectives. We believe that the evidence obtained provides a reasonable basis for our findings and conclusions based on our audit objectives.

Appendix A contains the details of our scope and methodology.

## **RESULTS OF AUDIT**

The Medicare payments that NHIC made to physicians in Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont for full vials of Herceptin furnished during CYs 2009 through 2011 were generally correct. Of the 113 line items reviewed, 111 were billed correctly. For the remaining 2 line items, physicians either reported incorrect units of service or did not provide supporting documentation for the services billed resulting in overpayments of \$2,513. NHIC has contacted the two physicians and initiated recovery of these overpayments. Consequently, this report contains no recommendations.

## **APPENDIX A: AUDIT SCOPE AND METHODOLOGY**

### **SCOPE**

Our audit covered 113 line items for 44 units of Herceptin furnished during CYs 2009 through 2011, which represent billings equivalent to entire multiuse vials. These line items represent \$240,028 in Medicare payments to 22 physicians from Jurisdiction 14. In this audit, we did not review entire claims; rather, we reviewed only the Herceptin line items within the claims.

We limited our review of NHIC's internal controls to those that were applicable to the 113 line items of service because our objective did not require an understanding of all internal controls over the submission and processing of claims. Our review allowed us to establish reasonable assurance of the authenticity and accuracy of the data obtained from CMS's National Claims History file, but we did not address the completeness of the file.

Our fieldwork was conducted from March 2012 through July 2012 and included contacting NHIC and all 22 physicians that received Medicare payments for the 113 line items.

### **METHODOLOGY**

To accomplish our objective, we:

- reviewed applicable Federal laws, regulations, and guidance;
- used CMS's National Claims History file to identify Part B line items which represented payments to physicians in Jurisdiction 14 for entire vials of Herceptin furnished during CYs 2009 through 2011;
- identified 113 line items with unit counts of 44;
- reviewed Common Working File records to determine whether any line items were adjusted prior to fieldwork;
- obtained medical records from 21 of the 22 physicians;
- reviewed the medical records the physicians furnished to determine whether each selected line item was billed correctly; and
- discussed the results of our review with NHIC.

We conducted this performance audit in accordance with generally accepted government auditing standards. Those standards require that we plan and perform the audit to obtain sufficient, appropriate evidence to provide a reasonable basis for our findings and conclusions based on our audit objectives. We believe that the evidence obtained provides a reasonable basis for our findings and conclusions based on our audit objectives.